Cargando…
JAK1抑制剂SHR0302和芦可替尼对骨髓增殖性肿瘤SET2细胞系和原代细胞增殖抑制和抗炎作用机制的研究
OBJECTIVE: To explore the effects and molecular mechanism of the selective JAK1inhibitor SHR0302 and Ruxolitinib on myeloproliterative neoplasms(MPN)cell line SET2 and primary cells in vitro. METHODS: Cell proliferation was detected by CCK8 kit. Colony forming experiment was conducted to evaluate er...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342687/ https://www.ncbi.nlm.nih.gov/pubmed/32023730 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.12.006 |
Ejemplares similares
-
免疫抑制剂FK506对肺癌细胞增殖和迁移的作用研究
Publicado: (2017) -
阿帕替尼联合CCI-779体外抑制小细胞肺癌细胞株NCI-H446的增殖和迁移
Publicado: (2020) -
PD 0332991对人内皮细胞增殖和凋亡的作用
Publicado: (2018) -
腺病毒介导的SD-HA对K562细胞增殖抑制和凋亡诱导的作用机制
Publicado: (2018) -
JAK抑制剂芦可替尼治疗中国骨髓纤维化患者的疗效和安全性:A2202随访一年结果
Publicado: (2016)